El-Naggar Mohamed Tarek, Hovaghimian Dikran Gilbert
Researcher, Research Institute of Ophthalmology, Giza, Egypt.
Electron Physician. 2017 Mar 25;9(3):3958-3965. doi: 10.19082/3958. eCollection 2017 Mar.
Laser vision correction for hyperopia is challenging. The purpose of the study was to assess the refractive outcomes of femtosecond-assisted laser in situ keratomileusis (LASIK) for hyperopic correction using wavefront-optimized ablation profiles.
This retrospective case series study included 20 Egyptian patients (40 eyes) with hyperopia or hyperopic astigmatism with a mean manifest refraction spherical equivalent (MRSE) of +2.55D±1.17 (range from +1.00 to +6.00) who had uneventful femtosecond-a assisted LASIK with wavefront-optimized aspheric ablation profile using refractive surgery suite (WaveLight FS200 Femtosecond Laser and WaveLight EX500 Excimer Laser) performed in the Research Institute of Ophthalmology and International Eye Hospital, Giza, Egypt. Statistical analysis was done using Microsoft Excel (Microsoft Corporation, Seattle, WA, USA).
The procedure significantly reduced the MRSE and cylinder post-operatively (95% were ± 0.50D and 100% ± 1.00 D), with stability of refraction and UDVA over the follow-up period (up to 12 months) after surgery. No eye lost any line of the CDVA, which reflects the excellent safety profile of the procedure; on the other hand, one eye (5%) gained one line and one eye (5%) even gained two lines. There were no significant complications during the procedure.
Femtosecond-assisted laser in situ keratomileusis for hyperopia showed predictable, effective, and safe refractive outcomes that were stable through 12 months. Longer follow-up period is required to detect any further regression.
远视的激光视力矫正具有挑战性。本研究的目的是评估使用波前优化消融轮廓的飞秒辅助准分子原位角膜磨镶术(LASIK)矫正远视的屈光效果。
这项回顾性病例系列研究纳入了20例埃及远视或远视散光患者(40只眼),平均明显屈光球镜等效度(MRSE)为+2.55D±1.17(范围为+1.00至+6.00),他们在埃及吉萨的眼科研究所和国际眼科医院使用屈光手术设备(威视FS200飞秒激光和威视EX500准分子激光)进行了飞秒辅助LASIK手术,采用波前优化非球面消融轮廓。使用微软Excel(美国华盛顿州西雅图市微软公司)进行统计分析。
该手术术后显著降低了MRSE和柱镜度数(95%在±0.50D以内,100%在±1.00D以内),术后随访期(长达12个月)屈光和最佳矫正视力(UDVA)稳定。没有眼睛丧失任何一行矫正视力(CDVA),这反映了该手术良好的安全性;另一方面,一只眼(5%)提高了一行视力,一只眼(5%)甚至提高了两行视力。手术过程中没有明显并发症。
飞秒辅助准分子原位角膜磨镶术矫正远视显示出可预测、有效且安全的屈光效果,在12个月内保持稳定。需要更长的随访期来检测是否有进一步的回退。